Atopic Dermatitis

Cynthia J. Trickett, PA-C, MPAS, discusses the personal and clinical effects of atopic dermatitis in adult and pediatric patients at the Maui Derm NP+PA 2022 Summer Conference in Colorado Springs, Colorado.

An extraordinary display of posters at this year's Society for Pediatric Dermatology annual conference.

From pediatric dermatology quizzes to the latest news in telederm to practical pearls on atopic dermatitis, alopecia, and vitiligo, there’s a lot going on at the SPD 2022 47th Annual Meeting, this year in Indianapolis, Indiana.

Lawrence Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children's Hospital-San Diego and professor of dermatology and pediatrics and vice-chair of the department of dermatology at UC San Diego School of Medicine, discusses new treatments and therapies for pediatric atopic dermatitis.

Click here to answer this week's poll.

Eric Simpson, MD, MCR, director of clinical research and dermatology professor at the Frances J. Storrs medical school at Oregon Health & Science University in Portland, Oregon, explains dives into what 2022 is bringing to the AD space.

Eric Simpson, MD, MCR, director of clinical research and dermatology professor at the Frances J. Storrs medical school at Oregon Health & Science University in Portland, Oregon, details the environment factors that could impact atopic dermatitis.

Here is what to expect from the “Getting to the Roots of Childhood Atopic Dermatitis” live virtual webinar happening June 23, 2022, at 6:00 PM EST.

At the 2022 SDPA Annual Summer Meeting, Lisa Swanson, MD, shared some fascinating patient presentations in pediatric dermatology.

A recent study showed that patients with atopic dermatitis have a higher prevalence of infertility, highlighting the need for clinicians to be wary of this increased risk and improve the care and management of this patient population.

Lawrence Eichenfield, MD, of Rady Children's Hospital-San Diego, who discusses the importance of multidisciplinary in the dermatology specialty.

Amy Paller, MD, chair of the Department of Dermatology at Northwestern University’s Feinberg School of Medicine, sits down to answer the important questions on this FDA approval.

Sanofi and Regeneron Pharmaceuticals, Inc announced the FDA approval of dupilumab. It is now the first biologic medicine for children from 6 months to 5 years old with moderate to severe atopic dermatitis

About 80% of patients treated with roflumilast foam 0.3% (ARQ-154, Arcutis Biotherapeutics Inc) met the primary endpoint of the trial.

In a video with Dermatology Times®, James Q. Del Rosso, DO, discusses his presentation “What’s News in the Medicine Chest” at the current 2022 Fall Clinical Dermatology Conference for PAs & NPs.

A poster presented at the current 2022 Fall Clinical Dermatology Conference for PAs & NPs showed normalization of skin barrier function in patients with moderate to severe atopic dermatitis taking dupilumab, according to the investigators.

Matthew Zirwas, MD, shares his step-by-step pearls for quelling this pruritic skin condition.

Patients with chronic inflammatory skin diseases do not have an increased risk of venous thromboembolism (VTE) compared to a matched healthy control cohort. This knowledge can be useful to clinicians when contemplating systemic immunomodulatory therapies in their dermatologic patients.

In this episode, the topics up for discussion include possible technologies to help atopic dermatitis patient adherence with treatment along with new strategies to improve patient experiences at the practice.

A look at the common condition and how to treat it.

At the 2022 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meeting, 4 health care professionals spoke of disease states in both women and children caused by climate change, and what physicians can do to mitigate this crisis.

Allergic contact dermatitis and atopic dermatitis are common causes of rashes in the pediatric population. Patch testing can help demystify the cause of such skin conditions and determine treatment.

In a presentation at New Wave Dermatology Conference, Matthew Zirwas, MD, delved into why atopic dermatitis (AD) should be the first condition that comes to mind when an adult patient presents with dermatitis, why presentation is different in pediatric and adult patients, and why treating AD is about more than quality of life.

A breakfast product theater at the 3rd Annual Society of Dermatology Nurse Practitioners Symposium, sponsored by Sanofi and Regeneron Pharmaceuticals, dove into the different manifestation of atopic dermatitis in skin of color and how to better recognize the disease in this patient population.

In this video interview, Andrew Blauvelt, MD, MBA, dives into the current state of atopic dermatitis treatment from his talk presented at the Annual Society of Dermatology Nurse Practitioners Symposium, held April 22-23, in Nashville, Tennessee.